ESMA Q&A update on MiFID II focuses on best execution of OTC products


Pan European regulatory authority ESMA has added new Q&As on the implementation of investor protection topics under the Market in Financial Instruments Directive and Regulation (MiFID II/ MiFIR).

MiFID II applies from January 2018 and will strengthen the protection of investors by both introducing new requirements and reinforcing existing ones. The purpose of the Q&A is to promote common supervisory approaches and practices in the application of MiFID II/ MiFIR for investor protection topics.

ESMA’s MiFID II Q&A provides clarifications on the following topics:

  • Suitability
  • Post sale reporting
  • Inducements (research)
  • Information on charges and costs

ESMA plans to continue to develop this Q&A approach on investor protection topics under MiFID II in the coming months, both adding questions and answers to the topics already covered and introducing new sections for other MiFID II investor protection areas not yet addressed in this Q&A.

The latest ESMA MiFID Q&A document can be accessed here.

Related News

arrow

ESMA Q&A update on MiFID II focuses on best execution of OTC products

2

Send this to a friend